Ongoing Clinical Trials for Cervix Carcinoma

There are currently 27 clinical trials exploring new treatment approaches for cervical cancer across multiple countries in Europe and beyond. These studies are investigating various therapeutic strategies including immunotherapies, targeted drugs, chemotherapy combinations, vaccines, and cell-based treatments for patients at different stages of the disease.

Clinical trial locations

Study Comparing ANV419 and High Dose IL2 in Adoptive Cell Therapy for Patients with Melanoma, Non-Small Cell Lung Cancer, and Cervical Cancer

This trial is testing a new treatment approach for advanced solid tumors including melanoma, non-small cell lung cancer, and cervical cancer. The study compares a new medication called ANV419 with traditional high-dose interleukin-2 treatment when used after adoptive cell therapy with tumor infiltrating lymphocytes.

Inclusion criteria: Patients must have confirmed advanced cancer that cannot be removed by surgery or has spread. The disease must have worsened after at least one standard treatment. Patients need good lung function, life expectancy of at least 3 months, and must test negative for HIV and hepatitis infections. Both women and men must use effective birth control during the study.

Exclusion criteria: Patients with other types of cancer not specified in the study cannot participate. Those with medical conditions that could interfere with treatment, inability to follow study procedures, recent participation in other trials, pregnancy or breastfeeding, severe allergic reactions to study medications, certain heart conditions, and active infections are excluded.

Main focus: The study evaluates whether ANV419 can reduce side effects commonly associated with high-dose IL-2 treatment while maintaining or improving treatment effectiveness. Researchers will monitor tumor response, quality of life, and safety throughout the treatment period.

Investigational drugs: ANV419 is an IL-2 analog being tested as an alternative to traditional high-dose IL-2 therapy. The goal is to provide similar or better cancer-fighting effects with fewer serious side effects.

Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

This trial investigates AZD9574, an experimental medication, both alone and combined with other anti-cancer treatments for patients with advanced or relapsed cancers. The study includes various cancer types with specific genetic mutations such as BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.

Inclusion criteria: Participants must be at least 18 years old with advanced cancer that has progressed after previous treatments. Women who can have children must have a negative pregnancy test and use highly effective birth control. Patients must have good overall health status and adequate organ function.

Exclusion criteria: Patients without the specific types of cancer being studied or without the required genetic mutations cannot participate. Those not within the specified age range or unable to safely participate due to other health conditions are excluded.

Main focus: The study assesses the safety and tolerability of AZD9574, determines optimal dosing, and evaluates how the body processes the drug. Researchers monitor tumor response and biomarkers to understand treatment effectiveness.

Investigational drugs: AZD9574 is an experimental oral medication being tested alone and in combination with other cancer treatments. The study aims to understand its safety profile and initial effectiveness against advanced malignancies.

Study of JK06 for Patients with Advanced or Metastatic Cancer

This trial tests JK06, an antibody-drug conjugate, in patients with various types of advanced cancers that cannot be surgically removed. The study includes cervical cancer among other solid tumor types.

Inclusion criteria: Patients must be at least 18 years old with confirmed advanced cancer that has spread or cannot be removed surgically. They must have tried standard treatments without success or be unable to receive them. Participants need at least one measurable tumor and adequate organ and bone marrow function.

Exclusion criteria: Patients with recent cancer treatment, certain health conditions interfering with the study, pregnancy or breastfeeding, allergies to study medication, inability to follow procedures, participation in other trials, certain heart conditions, uncontrolled infections, or substance abuse history are excluded.

Main focus: The study aims to determine the safest and most effective dose of JK06 while evaluating its ability to reduce tumor size or stop cancer growth. Regular monitoring assesses treatment response and safety.

Investigational drugs: JK06 is an experimental antibody-drug conjugate given intravenously every three weeks. It combines an antibody with a drug to specifically target and attack cancer cells.

Study on Fertility Preservation in Women with Stage IB2 Cervical Cancer Using Cisplatin, Carboplatin, and Paclitaxel Before Surgery

This trial explores fertility preservation in women with stage IB2 cervical cancer by using chemotherapy before surgery. The study aims to shrink tumors to allow fertility-sparing surgery.

Inclusion criteria: Women must be 18-40 years old, premenopausal, and wish to preserve fertility. They must have confirmed stage IB2 cervical cancer with tumors measuring 2-4 cm. Patients need good performance status and adequate organ function.

Exclusion criteria: Patients with cancer spread to lymph nodes, tumors larger than 4 cm, or men cannot participate. Those outside the specified age range or belonging to vulnerable populations are excluded.

Main focus: The study evaluates whether chemotherapy followed by fertility-sparing surgery can effectively treat cervical cancer while preserving the ability to have children. Researchers monitor tumor response and long-term outcomes.

Investigational drugs: The treatment combines cisplatin, carboplatin, and paclitaxel given intravenously before surgery to reduce tumor size and enable fertility preservation.

Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

This trial tests ifinatamab deruxtecan, a new medication, in patients with various recurrent or metastatic cancers including cervical cancer. The treatment is given as an intravenous infusion.

Inclusion criteria: Participants must be at least 18 years old with recurrent or metastatic solid tumors that have progressed after previous treatments. They must have at least one measurable tumor, good performance status, and adequate organ function. Patients must not have received certain prior treatments.

Exclusion criteria: Patients without recurrent or metastatic solid tumors, those without measurable target lesions, those outside the specified age range, or belonging to vulnerable populations cannot participate.

Main focus: The study evaluates the effectiveness and safety of ifinatamab deruxtecan by monitoring tumor response, progression-free survival, and side effects. Regular assessments track treatment impact.

Investigational drugs: Ifinatamab deruxtecan is an antibody-drug conjugate that targets specific proteins on cancer cells to deliver a toxic substance directly to them.

Study on Improving Cervical Dysplasia Diagnosis in Postmenopausal Women Using Estradiol

This trial investigates whether vaginal estrogen treatment before colposcopy can improve the diagnosis of cervical precancerous lesions in postmenopausal women.

Inclusion criteria: Women must be 50 years or older and postmenopausal, referred for colposcopy due to positive HPV test or abnormal cervical results. At least 6 months must have passed since any previous colposcopy with biopsies.

Exclusion criteria: Women who are not HPV positive, do not have cervical cell changes, are not postmenopausal, or are not within the specified age range cannot participate.

Main focus: The study aims to determine if vaginal estrogen pretreatment improves visibility and assessment during colposcopy, potentially enhancing early detection of cervical abnormalities and reducing cancer risk.

Investigational drugs: Vaginal estrogen is applied before colposcopic examination to improve tissue condition and diagnostic accuracy in postmenopausal women.

Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

This trial evaluates raludotatug deruxtecan in patients with advanced or metastatic gynecological cancers including cervical cancer, as well as genitourinary cancers.

Inclusion criteria: Adults 18 years or older with confirmed advanced cancer that has progressed after previous treatments. Patients must have at least one measurable tumor that can be biopsied, good performance status, and adequate organ function. Specific requirements vary by cancer type.

Exclusion criteria: Patients with advanced or metastatic solid tumors including certain gynecological and genitourinary cancers, those without specific genetic requirements, and individuals not meeting age or health criteria cannot participate.

Main focus: The study assesses the effectiveness and safety of raludotatug deruxtecan by monitoring tumor response, survival rates, and quality of life. Regular assessments evaluate treatment impact.

Investigational drugs: Raludotatug deruxtecan is an experimental medication given through intravenous infusion, designed to target and fight advanced cancer cells.

Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

This trial tests BAY 2927088, an oral medication, in patients with advanced solid tumors that have HER2 mutations. The study includes cervical cancer among other cancer types.

Inclusion criteria: Patients must be at least 18 years old with advanced cancer that cannot be surgically removed and has HER2-activating mutations. They must have tried standard treatments or have no satisfactory alternatives. At least one measurable tumor is required, along with good performance status and adequate organ function.

Exclusion criteria: Patients without HER2 mutations, those with other cancer types not in the study, individuals outside the age range, pregnant or breastfeeding women, those with certain allergies, medical conditions, recent surgeries, or substance abuse history cannot participate.

Main focus: The study determines the safety and effectiveness of BAY 2927088 by monitoring tumor response, side effects, and quality of life. Researchers evaluate optimal dosing and treatment duration.

Investigational drugs: BAY 2927088 is an oral tyrosine kinase inhibitor that blocks specific proteins helping cancer cells grow, potentially slowing tumor progression.

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

This trial tests volrustomig, a monoclonal antibody, in women with locally advanced cervical cancer who have not progressed after chemoradiation therapy.

Inclusion criteria: Women must be at least 15 years old, weigh more than 35 kg, and have confirmed stage IB2 cervical cancer with lymph node involvement. They must not have disease progression after chemoradiation and need adequate organ function. A tumor sample for PD-L1 testing is required.

Exclusion criteria: Patients with cancer spread to lymph nodes, tumors larger than 4 cm, men, those outside the age range, or belonging to vulnerable populations cannot participate.

Main focus: The study evaluates whether volrustomig can improve progression-free survival after chemoradiation, particularly in patients with PD-L1 expression. Researchers monitor disease progression and quality of life.

Investigational drugs: Volrustomig is an immunotherapy medication given intravenously that helps the immune system recognize and attack cancer cells by targeting the PD-L1 protein.

Study on the Effects of Carboplatin and Cisplatin in Patients with Early-Stage, Intermediate-Risk Cervical Cancer

This trial investigates whether adding chemotherapy and radiation after surgery helps patients with early-stage, intermediate-risk cervical cancer live longer without recurrence.

Inclusion criteria: Women aged 18-64 years with confirmed stage IB1 to IIA cervical cancer and specific tumor risk factors. Patients must have good performance status, be suitable for radical surgery followed by radiotherapy, have negative pregnancy test if applicable, and negative HIV test if from high-risk countries.

Exclusion criteria: Patients without early-stage, intermediate-risk cervical cancer, men, or those belonging to vulnerable populations cannot participate.

Main focus: The study determines if additional chemoradiation after surgery improves survival and prevents cancer recurrence compared to surgery alone. Researchers monitor long-term outcomes and quality of life.

Investigational drugs: The treatment uses carboplatin and cisplatin as chemotherapy, combined with radiation therapy after surgery to eliminate remaining cancer cells.

Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

This trial tests the combination of SKB264 and pembrolizumab in patients with advanced cervical cancer and other solid tumors. Both medications are given as intravenous infusions.

Inclusion criteria: Participants must be at least 18 years old with locally advanced or metastatic cancer that has progressed or returned after treatment. Both men and women can participate. Patients need good performance status and adequate organ function.

Exclusion criteria: Patients with severe allergic reactions to similar medications, uncontrolled medical conditions, pregnancy or breastfeeding, current participation in another trial, recent treatments affecting results, certain heart conditions, active infections, substance abuse history, or inability to follow procedures are excluded.

Main focus: The study evaluates the effectiveness and safety of combining SKB264 with pembrolizumab by monitoring tumor response, side effects, and survival rates.

Investigational drugs: SKB264 is an experimental drug being tested with pembrolizumab, an established immunotherapy that helps the immune system fight cancer cells.

Summary

The clinical trial landscape for cervical cancer shows significant activity across Europe, with 27 ongoing studies testing various therapeutic approaches. Several notable patterns emerge from these trials.

A substantial number of studies focus on immunotherapy approaches, particularly checkpoint inhibitors like pembrolizumab, atezolizumab, and dostarlimab. Many trials combine these immunotherapies with standard chemoradiation or chemotherapy regimens, suggesting a shift toward combination strategies for improved outcomes.

Geographically, trials are concentrated in Western European countries, with France, Spain, Italy, and Germany hosting the most studies. The Netherlands, Belgium, and several Scandinavian countries also participate actively in cervical cancer research. This distribution reflects both established oncology research infrastructure and patient population accessibility.

Several trials specifically address fertility preservation in younger women with early-stage disease, recognizing the importance of reproductive health for this patient population. These studies investigate whether neoadjuvant chemotherapy can enable fertility-sparing surgery.

Advanced disease stages receive considerable attention, with multiple studies targeting recurrent, metastatic, or persistent cervical cancer. Novel antibody-drug conjugates like tisotumab vedotin, ifinatamab deruxtecan, and raludotatug deruxtecan represent promising new treatment options being evaluated across multiple countries.

Prevention-focused trials include HPV vaccination studies in both primary prevention and post-treatment settings, reflecting continued emphasis on reducing disease burden through vaccination strategies.

The diversity of therapeutic agents under investigation—from cell therapies and vaccines to targeted small molecules and immunotherapies—demonstrates the multifaceted approach to improving cervical cancer treatment outcomes across all disease stages.

#1 Clinical Trials Search in Europe

Cervix carcinoma – Trials in Disease

Ongoing Clinical Trials for Cervix Carcinoma

Clinical trial locations

Study Comparing ANV419 and High Dose IL2 in Adoptive Cell Therapy for Patients with Melanoma, Non-Small Cell Lung Cancer, and Cervical Cancer

Study of AZD9574 and Temozolomide for Patients with Advanced Solid Tumors, Including Breast, Ovarian, Pancreatic, and Prostate Cancers

Study of JK06 for Patients with Advanced or Metastatic Cancer

Study on Fertility Preservation in Women with Stage IB2 Cervical Cancer Using Cisplatin, Carboplatin, and Paclitaxel Before Surgery

Study on Ifinatamab Deruxtecan for Patients with Recurrent or Metastatic Solid Tumors

Study on Improving Cervical Dysplasia Diagnosis in Postmenopausal Women Using Estradiol

Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

Study on the Effects of Carboplatin and Cisplatin in Patients with Early-Stage, Intermediate-Risk Cervical Cancer

Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

Summary

Ongoing Clinical Trials on Cervix carcinoma

Study on PET Imaging with Fianlimab and Cemiplimab for Patients with Advanced Solid Tumors, with or without Platinum-Based Chemotherapy

Study Comparing ANV419 and High Dose IL2 in Adoptive Cell Therapy for Patients with Melanoma, Non-Small Cell Lung Cancer, and Cervical Cancer

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

Evaluation of pembrolizumab and bevacizumab in patients with metastatic cervical cancer

Study of cemiplimab with chemoradiotherapy for patients with locally advanced cervical cancer

A study of pembrolizumab and lenvatinib for patients with high risk locally advanced cervical cancer after chemoradiotherapy and brachytherapy

Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

Study of NP137 with carboplatin, paclitaxel and pembrolizumab combination therapy for patients with advanced endometrial or cervical cancer who had prior chemotherapy

Study on Atezolizumab for Patients with Locally Advanced Cervical Cancer

Study on Tisotumab Vedotin, Bevacizumab, Carboplatin, and Pembrolizumab for Patients with Recurrent or Stage IVB Cervical Cancer

Connected medications:

Cervix carcinoma – Trials in Disease

Ongoing Clinical Trials for Cervix Carcinoma

Clinical trial locations

Summary

Ongoing Clinical Trials on Cervix carcinoma

More information aboutCervix carcinoma:

Connected medications:

We use cookies

More information about
Cervix carcinoma: